Protective effect of genistein on proliferative vitreoretinopathy

Objective To investigate the preventing effect of genistein on proliferative vitreoretinopathy． Methods Twentyfour healthy New Zealand white rabbits were selected randomly and divided into three groups: blank group, model group (blood therapy+0．9% sodium chloride accouting for 0．1 ml) and experimental group (blood therapy+40 mg/L genistein accounting for 0．1 ml)． Changes in vitreous body and retina were observed with silt lamp microscope and funduscope． The eyes were enucleated to make samples for optical microscope for observing pathological changes of the retina by HE staining on the 28th day after injection of drug． The content of platelet-derived growth factor (PDGF) and epidermal growth factor (EGF) was measured by ELISA． Results Hyperplasia level of vitreous and retina in experiment group was significantly lower than model group on the 14th, 21th and 28th day (0．69% vs 2．54%; 0．93% vs 3．00%; 1．06% vs 3．13%; P< 0．05)． The contents of PDGF and EGF in experiment group were significantly lower than model group and blank group (180．45±38．99) pg/ml and (79．29±24．77) pg/ml vs (349．98±67．36) pg/ml; (1．215±0．087) μg/L and (0．192±0．385) μg/L vs (0．367±0．06) μg/L, P< 0．05． Conclusion Intravitreal injection of genistein has obvious inhibitory to proliferative vitreoretinopathy (PVR)．